Compugen Ltd. (CGEN) Fair Value 2026

CGEN · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

9.0 /10

32 fundamental signals · 9 models active

Value Trap Risk

SAFE (18/100)

Quick Summary — As of 2026-08-27, Compugen Ltd. (CGEN) trades at $2.76, versus a $2.05 median fair value across its 9 active models — 25.8% below the current price. QOC: 9.0/10. Value Trap Risk: 18/100 (SAFE). 9/13 models active. Within that set, the Bayesian DCF component alone returns $1.68.

Key Facts

Ticker
CGEN
Price
$2.76
Quality Score
9.0/10
Value Trap Risk
18/100
Models Active
9/13
Last Updated
Strength: Quality Score of 9.0/10 indicates strong fundamentals
Risk: Majority of models suggest overvaluation

Is Compugen Ltd. (CGEN) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, Compugen Ltd. (CGEN) appears overvalued as of : the median of 9 independent fair value estimates is $2.05, 25.8% below the current price of $2.76. Estimates range from $1.39 to $2.88. CGEN scores 9.0/10 on fundamental quality and 18/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. CGEN’s -25.8% gap is wider than that market norm, and the Biotechnology sector median is -64.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Compugen Ltd. Stock in 2026? →

What Fair Value Does Each Model Give CGEN?

9 Intrinsic Value Models vs. Current Price ($2.76)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $1.68 -39.2%
Ensemble · Low Conviction
 $2.05 -25.8%
Scenario · Medium Conviction
 $2.73 -1.3%
Intrinsic · Medium Conviction
 $1.39 -49.7%
Unlock the Full Matrix

Access 5 additional models including EROIC Spread, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is CGEN's Fair Value Range?

Spread across 9 independent models · $1.39 to $2.88

CirclFi's 9 active models place Compugen Ltd. (CGEN) between $1.39 and $2.88 per share, a spread of 73% of the median. The median of that range — $2.05 — is the fair value CirclFi publishes for CGEN, against a current price of $2.76.

Low · ML-RIVHigh · EROIC
$1.39median $2.05$2.88
Where the range comes from
Most bearish modelML Residual Income$1.39
Most bullish modelEROIC Spread$2.88
Model agreement0 bullish · 6 bearishmoderate

A band of this width is typical. The methods agree on direction but weight growth, reinvestment and risk differently, so treat the median as a centre of gravity rather than a precise target.

Every figure above is one model's standalone output on CGEN, not a CirclFi price target. How each model works →

What Is Compugen Ltd. (CGEN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Compugen Ltd. at its current price of $2.76. The median intrinsic value is estimated at $2.05 (-25.8% vs price), with 6 models flagging overvaluation risk. The most optimistic model, EROIC, places fair value at $2.88 (+4.2%), while ML-RIV — the most conservative — estimates $1.39 (-49.7%). This +53.9% gap reflects genuine analytical uncertainty about Compugen Ltd.'s intrinsic worth.

What Do the Models Say About CGEN?

9 of 13 models are currently active for CGEN. Of these, 1 model suggests upside while 8 models suggest overvaluation. Taken together, their median fair value for CGEN is $2.05 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $1.68 on its own, implying -39.2% downside from the current price. See which stocks rank higher →

How Does CGEN Rank in Biotechnology?

Among 620 Biotechnology stocks, CGEN ranks #10 by Quality of Company score. CirclFi's QOC score of 9.0/10 evaluates 32 fundamental signals. A score of 9.0 places CGEN in the top tier.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Compugen Ltd. competes in an environment where partnership revenue often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is CGEN a Value Trap?

CirclFi's Value Trap algorithm assigns CGEN a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for Compugen Ltd.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Compugen Ltd. is rated at 9.0/10. This strong-tier score demonstrates strong fundamentals across the majority of our quality signals.

The gap between the most bullish and bearish model spans +53.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CGEN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CGEN's 9 active models, average confidence is 36%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Compugen Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

CRMDCorMedix Inc.QOC 9.0VCELVericel CorporationQOC 8.8ONCBeOne Medicines AGQOC 9.0PBYIPuma Biotechnology, Inc.QOC 8.7VRTXVertex Pharmaceuticals IncorporatedQOC 9.1PTCTPTC Therapeutics, Inc.QOC 8.7CELZCreative Medical Technology Holdings, Inc.QOC 5.9IMRXImmuneering CorporationQOC 5.0COCPCocrystal Pharma, Inc.QOC 4.4EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: CRMD · VCEL · ONC · PBYI · VRTX · PTCT · CELZ · IMRX · COCP · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CGEN?

7 companies across all industries closest to CGEN’s Quality of Company score of 9.0/10.

GASSStealthGas Inc.QOC 9.0DRSLeonardo DRS, Inc.QOC 9.0CRHCRH plcQOC 9.0GHMGraham CorporationQOC 9.0GGenpact LimitedQOC 9.0GCMGGCM Grosvenor Inc.QOC 9.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GASS · DRS · CRH · GHM · G · GCMG · NVDA

Where Does CGEN Sit in CirclFi's Biotechnology Rankings?

CGEN is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Compugen Ltd.’s Valuation?

What is Compugen Ltd.'s intrinsic value in 2026?

CirclFi puts Compugen Ltd. (CGEN)'s intrinsic value at $2.05 — the median of 9 independent model estimates as of 2026-08-27, ranging from $1.39 to $2.88. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $1.68 on its own. The Quality of Company score is 9.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CGEN overvalued or undervalued right now?

At $2.76, 1 of 9 active models suggest CGEN may be undervalued, while 8 indicate potential overvaluation. The median of all 9 fair value estimates is $2.05, 25.8% below the current price of $2.76 — a consensus view that CGEN is overvalued. The assessment depends on which methodology best fits Compugen Ltd.'s business model in Biotechnology.

What does a Quality of Company score of 9.0 mean for CGEN?

Compugen Ltd.'s QOC of 9.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on CGEN?

CirclFi analyzes CGEN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on CGEN?

Of the 9 models currently active on CGEN, EROIC Spread is the most bullish at $2.88 per share, and ML Residual Income is the most bearish at $1.39. CirclFi's published fair value for CGEN is the median of that range, $2.05, not either extreme. The gap between the two ends equals 73% of the median — a normal spread for a company of this profile. Browse stocks by value-trap risk →

Is CGEN a value trap in 2026?

Compugen Ltd.'s Value Trap score is 18/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 9-model valuation engine, Compugen Ltd. (CGEN) has a median fair value of $2.05 — 25.8% below the current price of $2.76 — as of 2026-08-27.” Source: circlfi.com/stock/CGEN/ · Methodology
Primary sources for this CGEN valuation
  • Financial statements: Compugen Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001119774) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CGEN as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on CGEN.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

5 models hidden for CGEN Unlock All 9 — $39/mo